Prospective changes in financial toxicity and health-related quality of life in patients with gynecologic cancer.

Background: Financial toxicity impacts the treatment choices, daily life, and health-related quality of life (HRQoL) of cancer patients. We investigated future variations in financial toxicity and HRQoL of patients with gynecologic cancer, evaluated using the COmprehensive Score for financial Toxicity (COST) questionnaire.

Methods: This multicenter study enrolled patients with gynecologic cancer incurring co-payments for anti-cancer drug treatment for over 2 months.

Validity and reliability of the Integrated Palliative Care Outcome Scale for non-cancer patients.

Aim: This study assessed the validity and reliability of the Integrated Palliative Care Outcome Scale for non-cancer patients.

Methods: We recruited 223 non-cancer patients receiving palliative care and their healthcare providers (222) across two home care facilities and two hospitals for a cross-sectional study. We assessed the construct validity and known-group validity of the Integrated Palliative Care Outcome Scale.

Development of a Japanese Scale that Evaluates the Level of Nursing Support Provided to Patients for Decision-Making in Cancer Clinical Trials.

Clinical nurses need learning programs that are useful in nursing support for patients' decision-making (NSPDM) regarding cancer clinical trials (CCTs). The usefulness of the learning program can be evaluated if the practices of NSPDM before and after participation in the learning program can be compared. We developed a scale to measure the level of self-assessed NSPDM regarding participation in a CCT.

Association between financial toxicity and health-related quality of life of patients with gynecologic cancer.

Objectives: Patients often struggle with their financial situation during cancer treatment due to treatment-related costs or loss of income. This resulting negative effect is called financial toxicity, which is a known as a side effect of cancer care. This study aimed to evaluate the association between financial toxicity and health-related quality of life among patients with gynecologic cancer using validated questionnaires.

Validity of the COmprehensive Score for financial Toxicity (COST) in patients with gynecologic cancer.

Objective: Financial toxicity is a financial burden of cancer care itself, which leads to worse quality of life and higher mortality and is considered an adverse effect. The COmprehensive Score for financial Toxicity (COST) tool is a patient-reported outcome measurement used to evaluate financial toxicity. We aimed to validate the internal consistency and reproducibility of the COST tool in patients with gynecologic cancer.

Searching for a way to live to the end: decision-making process in patients considering participation in cancer phase I clinical trials.

Purpose/objectives: To reveal the decision-making process in patients considering participation in cancer phase I clinical trials.

Design: Grounded theory approach.

Setting: Cancer center in a metropolitan area of Tokyo, Japan.